167 related articles for article (PubMed ID: 37324467)
1. Impact of CYP2D6 genotype on opioid use disorder deprescription: an observational prospective study in chronic pain with sex-differences.
Muriel J; Barrachina J; Del Barco G; Carvajal C; Escorial M; Margarit C; Ballester P; Peiró AM
Front Pharmacol; 2023; 14():1200430. PubMed ID: 37324467
[No Abstract] [Full Text] [Related]
2. Long-term deprescription in chronic pain and opioid use disorder patients: Pharmacogenetic and sex differences.
Muriel J; Escorial M; Margarit C; Barrachina J; Carvajal C; Morales D; Peiró AM
Acta Pharm; 2023 Jun; 73(2):227-241. PubMed ID: 37307374
[TBL] [Abstract][Full Text] [Related]
3. Clinical prediction of opioid use disorder in chronic pain patients: a cohort-retrospective study with a pharmacogenetic approach.
Escorial M; Muriel J; Agulló L; Zandonai T; Margarit C; Morales D; Peiró AM
Minerva Anestesiol; 2024 May; 90(5):386-396. PubMed ID: 38619184
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics and prediction of adverse events in prescription opioid use disorder patients.
Muriel J; Margarit C; Barrachina J; Ballester P; Flor A; Morales D; Horga JF; Fernández E; Peiró AM
Basic Clin Pharmacol Toxicol; 2019 Apr; 124(4):439-448. PubMed ID: 30549211
[TBL] [Abstract][Full Text] [Related]
5. Use of CYP2D6 substrates and inhibitors during pain management with analgesic opioids: Drug-drug interactions that lead to lack of analgesic effectiveness.
Muriel J; Escorial M; Carratalá C; Margarit C; Barrachina J; López A; Gallardo E; Kringen MK; Peiró AM
Biomed Pharmacother; 2024 Jul; 176():116882. PubMed ID: 38876046
[TBL] [Abstract][Full Text] [Related]
6. Association of
Merchant S; Prows CA; Yang F; Ding L; MacDonald J; Zhang X; Sadhasivam S; Garcia V; Sturm P; Chidambaran V
Ann Transl Med; 2022 Dec; 10(23):1262. PubMed ID: 36618804
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication.
Kirchheiner J; Schmidt H; Tzvetkov M; Keulen JT; Lötsch J; Roots I; Brockmöller J
Pharmacogenomics J; 2007 Aug; 7(4):257-65. PubMed ID: 16819548
[TBL] [Abstract][Full Text] [Related]
8. Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics.
Gan SH; Ismail R; Wan Adnan WA; Zulmi W
Mol Diagn Ther; 2007; 11(3):171-81. PubMed ID: 17570739
[TBL] [Abstract][Full Text] [Related]
9. Gender based differences, pharmacogenetics and adverse events in chronic pain management.
Planelles B; Margarit C; Inda MD; Ballester P; Muriel J; Barrachina J; Ajo R; Esteban MD; Peiró AM
Pharmacogenomics J; 2020 Apr; 20(2):320-328. PubMed ID: 31745220
[TBL] [Abstract][Full Text] [Related]
10. Oxycodone/naloxone versus tapentadol in real-world chronic non-cancer pain management: an observational and pharmacogenetic study.
Barrachina J; Margarit C; Muriel J; López-Gil S; López-Gil V; Vara-González A; Planelles B; Inda MD; Morales D; Peiró AM
Sci Rep; 2022 Jun; 12(1):10126. PubMed ID: 35710811
[TBL] [Abstract][Full Text] [Related]
11. CYP2D6 phenotypes and opioid metabolism: the path to personalized analgesia.
Ballester P; Muriel J; Peiró AM
Expert Opin Drug Metab Toxicol; 2022 Apr; 18(4):261-275. PubMed ID: 35649041
[TBL] [Abstract][Full Text] [Related]
12. Sex Differences in Oxycodone/Naloxone vs. Tapentadol in Chronic Non-Cancer Pain: An Observational Real-World Study.
Barrachina J; Margarit C; Muriel J; López-Gil V; López-Gil S; Ballester P; Mira-Lorente L; Agulló L; Peiró AM
Biomedicines; 2022 Oct; 10(10):. PubMed ID: 36289731
[TBL] [Abstract][Full Text] [Related]
13.
St Sauver JL; Olson JE; Roger VL; Nicholson WT; Black JL; Takahashi PY; Caraballo PJ; Bell EJ; Jacobson DJ; Larson NB; Bielinski SJ
Pharmgenomics Pers Med; 2017; 10():217-227. PubMed ID: 28769582
[TBL] [Abstract][Full Text] [Related]
14.
Dagostino C; Allegri M; Napolioni V; D'Agnelli S; Bignami E; Mutti A; van Schaik RH
Pharmgenomics Pers Med; 2018; 11():179-191. PubMed ID: 30425549
[TBL] [Abstract][Full Text] [Related]
15. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Zhou SF
Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
[TBL] [Abstract][Full Text] [Related]
16. CYP2D6 genotype dependent oxycodone metabolism in postoperative patients.
Stamer UM; Zhang L; Book M; Lehmann LE; Stuber F; Musshoff F
PLoS One; 2013; 8(3):e60239. PubMed ID: 23555934
[TBL] [Abstract][Full Text] [Related]
17. OPRM1 Gene Interaction with Sleep in Chronic Pain Patients Treated with Opioids.
Margarit C; Ballester P; Inda MD; Roca R; Gomez L; Planelles B; Ajo R; Morales D; Peiro AM
Pain Physician; 2019 Jan; 22(1):97-107. PubMed ID: 30700073
[TBL] [Abstract][Full Text] [Related]
18. Does co-administration of paroxetine change oxycodone analgesia: An interaction study in chronic pain patients.
Lemberg KK; Heiskanen TE; Neuvonen M; Kontinen VK; Neuvonen PJ; Dahl ML; Kalso EA
Scand J Pain; 2010 Jan; 1(1):24-33. PubMed ID: 29913934
[TBL] [Abstract][Full Text] [Related]
19. CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study.
VanderVaart S; Berger H; Sistonen J; Madadi P; Matok I; Gijsen VM; de Wildt SN; Taddio A; Ross CJ; Carleton BC; Hayden MR; Koren G
Ther Drug Monit; 2011 Aug; 33(4):425-32. PubMed ID: 21743374
[TBL] [Abstract][Full Text] [Related]
20. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
Zhou SF
Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
